156 related articles for article (PubMed ID: 29084478)
1. Translational health economics: The key to accountable adoption of in vitro diagnostic technologies.
Price CP; Wolstenholme J; McGinley P; St John A
Health Serv Manage Res; 2018 Feb; 31(1):43-50. PubMed ID: 29084478
[TBL] [Abstract][Full Text] [Related]
2. The impact of the UK NHS purchaser-provider split on the 'rational' introduction of new medical technologies.
Rosen R; Mays N
Health Policy; 1998 Feb; 43(2):103-23. PubMed ID: 10177613
[TBL] [Abstract][Full Text] [Related]
3. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies.
Ling DI; Lynd LD; Harrison M; Anis AH; Bansback N
J Comp Eff Res; 2019 Jan; 8(1):7-19. PubMed ID: 30525982
[TBL] [Abstract][Full Text] [Related]
4. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
[TBL] [Abstract][Full Text] [Related]
5. Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: a systematic review.
Polisena J; Clifford T; Elshaug AG; Mitton C; Russell E; Skidmore B
Int J Technol Assess Health Care; 2013 Apr; 29(2):174-84. PubMed ID: 23514665
[TBL] [Abstract][Full Text] [Related]
6. Budget impact analysis.
Leelahavarong P
J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
[TBL] [Abstract][Full Text] [Related]
7. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
8. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
9. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
Haas M; Hall J; Viney R; Gallego G
Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
[TBL] [Abstract][Full Text] [Related]
10. Prioritisation of specialist health care services; not NICE, not easy but it can be done.
Anderson P; Webb P; Groves S
Health Policy; 2017 Sep; 121(9):978-985. PubMed ID: 28797706
[TBL] [Abstract][Full Text] [Related]
11. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
Ijzerman MJ; Steuten LM
Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
[TBL] [Abstract][Full Text] [Related]
12. A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR DEVICES: THE FIRST FIVE YEARS.
Campbell B; Dobson L; Higgins J; Dillon B; Marlow M; Pomfrett C
Int J Technol Assess Health Care; 2017 Jan; 33(1):19-24. PubMed ID: 28502278
[TBL] [Abstract][Full Text] [Related]
13. Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
Drummond M
Value Health; 2016; 19(5):525-30. PubMed ID: 27565268
[TBL] [Abstract][Full Text] [Related]
14. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
[TBL] [Abstract][Full Text] [Related]
15. Sustainability in Health care by Allocating Resources Effectively (SHARE) 2: identifying opportunities for disinvestment in a local healthcare setting.
Harris C; Allen K; King R; Ramsey W; Kelly C; Thiagarajan M
BMC Health Serv Res; 2017 May; 17(1):328. PubMed ID: 28476159
[TBL] [Abstract][Full Text] [Related]
16. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
[TBL] [Abstract][Full Text] [Related]
17. Predictive validation of modeled health technology assessment claims: lessons from NICE.
Belsey J
J Med Econ; 2015; 18(12):1007-12. PubMed ID: 26548424
[TBL] [Abstract][Full Text] [Related]
18. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
Trosman JR; Weldon CB; Douglas MP; Deverka PA; Watkins JB; Phillips KA
Value Health; 2017 Jan; 20(1):40-46. PubMed ID: 28212967
[TBL] [Abstract][Full Text] [Related]
19. Anatomy of a value proposition for laboratory medicine.
Price CP; St John A
Clin Chim Acta; 2014 Sep; 436():104-11. PubMed ID: 24880041
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis and formulary decision making in England: findings from research.
Williams IP; Bryan S
Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
